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Background: A troubling number of health care-acquired infection outbreaks and transmission events,
some involving highly resistant microbial pathogens and resulting in serious patient outcomes, have been
traced to reusable, high-level disinfected duodenoscopes in the United States. The Food and Drug Ad-
ministration (FDA) requested a study be conducted to verify liquid chemical sterilization eﬃcacy of SYSTEM
1E® Liquid Chemical Sterilant Processing System (STERIS Corporation, Mentor, OH)with varied duodenoscope
designs under especially arduous conditions. Here, we describe the system’s performance under worst
case SYSTEM 1E® processing conditions.
Methods: The test protocol challenged the system’s performance by running a fractional cycle to eval-
uate reduction of recoverable test spores from heavily contaminated endoscopes, including all channels
and each distal tip, under worst case SYSTEM 1E® processing conditions.
Results: All devices were successfully liquid chemically sterilized, showing greater than a 6 log10 reduc-
tion of Geobacillus stearothermophilus spores at every inoculation site of each duodenoscope tested, in
less than half the exposure time of the standard cycle.
Conclusions: The successful outcome of the additional eﬃcacy testing reported here indicates that the
SYSTEM 1E® is an effective low-temperature liquid chemical sterilization method for duodenoscopes and
other critical and semicritical devices. It offers a fast, safe, convenient processing alternative while pro-
viding the assurance of a system expressly tested and cleared to achieve liquid chemical sterilization of
speciﬁc validated duodenoscope models.
© 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier
Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
In recent years a troubling number of health care-acquired in-
fection outbreaks and transmission events, some involving highly
resistant microbial pathogens and resulting in serious patient out-
comes, have been traced to reusable, high-level disinfected
duodenoscopes in the United States.1,2 These events have report-
edly not been limited to 1 particular scope model, design, or
manufacturer nor to a particular high-level disinfection modality,
and no single lapse in recommended cleaning or reprocessing prac-
tices has been implicated as a single cause. Epidemiologic evidence
around many of these outbreaks continues to be investigated.
In an ongoing effort to address the risks associated with the use
of these devices, the Food and Drug Administration (FDA) con-
vened a Gastroenterology-Urology Devices Advisory Panel Meeting
during May 20153 that sought to bring scientiﬁc and clinical knowl-
edge to bear on this public health issue. The summary from that
FDA meeting4 indicates that the majority of the panel believes it is
necessary to reclassify duodenoscopes, based on the Spaulding Clas-
siﬁcation, from semicritical devices to critical medical devices.
Accordingly, the majority support a move from acceptance of high-
level disinfection for these devices toward sterilization as the
reprocessing standard.
It is important to note that high-level disinfection had previ-
ously been considered an acceptable alternative when sterilization
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This study was conducted at the request of Food and Drug Administration to
verify liquid chemical sterilization eﬃcacy of SYSTEM 1E with varied duodenoscope
designs under especially arduous conditions. The test protocol challenged the sy-
stem’s performance by running a fractional cycle to evaluate spore reduction in heavily
contaminated endoscopes, including all channels and each distal tip, under worst
case SYSTEM 1E processing conditions. The devices were not cleaned after they were
inoculated; they were placed directly in the SYSTEM 1E for processing. The data re-
sulting from the protocol demonstrated that all devices were successfully liquid
chemically sterilized, showing greater than a 6 log10 reduction of Geobacillus
stearothermophilus spores at every inoculation site of each duodenoscope tested in
less than half the exposure time of the standard cycle.
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could not practically be achieved.5 This requirement for a higher stan-
dard of reprocessing in patient care is also reﬂected in the FDA’s
2015 ﬁnal guidance to industry, Reprocessing Medical Devices in Health
Care Settings: Validation Methods and Labeling,6 which speciﬁes that
semicritical devices should be sterilized unless the device design
prohibits sterilization.
The Gastroenterology-Urology Devices Advisory Panel dis-
cussed alternatives to high-level disinfection currently available for
reprocessing duodenoscopes. The sterilization options mentioned
included low-temperature sterilization modalities only, because
current duodenoscope designs are unable to withstand high-
temperature sterilization processes.
One option available is use of ethylene oxide (EO) for steriliza-
tion. EO is a time-honored sterilization method, but it requires
lengthy processing and aeration time, and is associated with em-
ployee health and safety risks. To date, no EO processor in the United
States has been cleared with a speciﬁc indication for sterilization
of duodenoscopes. In addition, users report that endoscopes expe-
rience a shortened use life due to material degradation issues when
processed repeatedly in EO. There is also a risk of patient and staff
toxicity if these devices are not aerated correctly to remove gas re-
siduals following the sterilization process. For these reasons, EO is
a less frequently used option and is not readily available in many
health care facilities.
Another low-temperature sterilization option is the use of liquid
chemical sterilants. There are numerous liquid chemical sterilants
cleared for device sterilization.7 However, the exposure time re-
quired to achieve sterilization for most of these formulations is
far longer than practical; therefore, it is our understanding that
these chemistries are commonly used for high-level disinfection
only.
There is a single FDA-cleared alternative that provides liquid
chemical sterilization within a 23-minute validated cycle. The
SYSTEM 1E® Liquid Chemical Sterilant Processing System (STERIS
Corporation, Mentor, OH) is the only system that is cleared in the
United States speciﬁcally for liquid chemical sterilization of cleaned,
immersible, reusable, heat-sensitive critical and semicritical medical
devices, including ﬂexible endoscopes such as duodenoscopes. The
system uses S40™ Sterilant Concentrate (STERIS Corporation, Mentor,
OH), a peracetic acid-based chemistry, with every processing cycle.
Following exposure to the sterilant, the devices are automatically
rinsed to remove sterilant residuals. The rinse water is produced
at the point of use from a potable water source through an exten-
sive treatment process unique to SYSTEM 1E that removes or
inactivates bacteria, viruses, protozoa, and fungi to ensure the device
is safe for immediate patient use.
FDA noted in their executive summary for the Panel meeting that
they have made recommendations to manufacturers of endo-
scope reprocessing systems to perform additional, rigorous testing
with more robust reprocessing protocols to enhance the safety
margin associated with duodenoscope use.4 STERIS therefore has
recently conducted supplemental testing with SYSTEM 1E to chal-
lenge the process under extreme spore loading conditions, mimicking
worst case clinical use, when processing duodenoscopes from 2




The objective was to perform triplicate test runs on a range of
at least 3 duodenoscope models that included devices manufac-
tured by more than a single manufacturer, and included at least 1
of each type of elevator wire channel design (ie, both open and
closed/sealed designs). The devices were selected based on their
availability at the time of testing and included Olympus TJF-160F,
Olympus TJF-Q180V (Olympus, Center Valley, PA), and Pentax
ED-3490TK (Pentax Medical, Tokyo, Japan).
Test method development and validation
A test method was developed and validated to provide a deﬁned,
reproducible, high-titer inoculation of bacterial spores into each in-
ternal channel and at the distal tip of each device. Each manually
cleaned duodenoscope was inspected before testing and was then
inoculatedwith an aqueous Geobacillus stearothermophilus spore sus-
pension containing 5% serum in 400 ppm AOAC International
(Rockville, MD) hardwater with a titer of 1.19 × 108 CFU/mL. All chan-
nels of each endoscope (biopsy, suction, air/water, air pipe if present,
and elevator wire if present) were inoculated by ﬂushing approx-
imately 0.5mL spore suspension through the port and through each
channel. The distal tip was then placed into the liquid inoculum and
the inoculum was suctioned up through the suction barb with a
syringe. During inoculation, biopsy forceps were placed into the
device biopsy channel to simulate clinical use. The distal tip of the
endoscopewas directly placed in the liquid inoculum for >30 seconds,
and the elevator mechanism was set to the fully open position and
then to the fully closed position at least three times with the biopsy
forceps in place. The inoculated device was then allowed to dry >60
minutes.
To validate the inoculation procedure to provide a consistent re-
coverable spore burden on each device, the inoculation process
described above was performed 3 times on each site of each device,
and immediately harvested after the drying step as described below
in the Sample recovery section. Mean recoverable test organisms
achieved per site ranged from 7.0 × 106-1.9 × 108.
The standard recovery of low levels of organisms (10-100 CFU/
device channel) was also validated for each test device. The validated
eﬃciency of recovery ranged from 84%-101% for the duodenoscopes
tested.
Test challenges
For each test cycle (three per device) the device was cleaned, in-
oculated, and dried as described above. The dried device was then
placed in a SYSTEM 1E C1160E Universal Flexible Processing Tray.
The appropriate SYSTEM 1E Quick Connect; that is, labeled specif-
ically for processing that model of duodenoscope in that tray, was
connected to the device according to its instructions for use. The
elevator mechanism was placed in a position halfway between its
extremes for processing in accordance with the device manufactu-
rer’s instructions for use. The SYSTEM 1E processing cycle was
initiated under the following worst case test conditions: S40 Ster-
ilant Concentrate represented its end-of-shelf-life concentration of
peracetic acid, the pump output provided ﬂow conditions repre-
senting the lowest ﬂow rate that is likely to be experienced under
normal operating conditions, the ultraviolet light system was set
at or below its lowest acceptable intensity, and the system used in-
comingwater at a temperature that would result in the shortest total
contact time. The liquid chemical sterilization cycle was cancelled
after 2.5 minutes of exposure to the sterilant use dilution, a time
less than half of the full cycle exposure time of 6 minutes. Samples
were immediately recovered from each inoculated site using a vali-
dated neutralization method as described below.
Sample recovery
Each test device was immediately harvested using 0.265%
sodium thiosulfate in a procedure validated to achieve effective
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neutralization of the liquid chemical sterilant. A channel-opening
brush was immersed into approximately 50mL sterile sodium thio-
sulfate in a sterile specimen cup. The elevator mechanism was
positioned in the lowered/closed position and vigorously brushed
with the channel-opening brush.8 The brush was remoistened in the
sodium thiosulfate, and the elevator mechanism was repositioned
to the raised/opened position and vigorously brushed again with
the channel-opening brush over the specimen cup containing the
sterile sodium thiosulfate. The handle of the brush was cut off and
the brush was immersed into the ~50mL sterile sodium thiosulfate.
The biopsy/suction channel was ﬂushed with 20 mL sterile
sodium thiosulfate and air through the channel and out the distal
tip into a sterile empty test tube. The air/water channel and, for
Olympus devices, the air pipe channels were similarly harvested.
The Olympus TJF-160F is the only device tested that had an open
elevator wire channel; for this device only the elevator wire channel
was harvested using 10 mL sterile sodium thiosulfate and air by
ﬂushing from the elevator port and collection from the distal tip
into a sterile empty test tube.
All harvested samples were ﬁltered through 0.45 micron ﬁlters.
Each ﬁlter was plated onto tryptic soy agar followed by incuba-
tion at 56oC · 2oC for 7 days. Results were recorded (Table 1).
RESULTS
The recoverable inoculation levels (positive controls) in each test
channel and distal tip were all in excess of 6 log10, and ranged from
6.8-8.3 log10 per site. Each channel of every duodenoscope tested
as well as each distal end/elevator mechanism showed greater than
a 6 log10 reduction at an exposure time less than half of SYSTEM
1E’s standard liquid chemical sterilization cycle. Positive and neg-
ative controls on all media performed as expected, meeting the
acceptance criteria for the test controls.
DISCUSSION
In early 2015, FDA approached endoscope manufacturers and
manufacturers of automated endoscope reprocessors with re-
quests to perform specially designed, challenging protocols for testing
duodenoscope reprocessing systems to establish greater conﬁ-
dence in their safe and effective use. These requests applied to
reprocessing systems already cleared by FDA and currently in use
in US health care facilities. Following discussion and subsequent
agreement on the protocol with FDA, STERIS agreed to design, val-
idate, and execute a suitable test protocol for the SYSTEM 1E Liquid
Chemical Sterilant Processing System based on FDA’s proposed test
model, using a range of duodenoscopes. The outcome of that testing
for 3 test trials on each of 3 duodenoscopes representing varied
designs is reported here. A limitation of this work is that only 3 rep-
etitions of the test were performed on 3 endoscope models. To
provide more data, additional testing was performed and will be
reported at a later date. A further limitation of the study is that it
did not evaluate clinically soiled, manually cleaned duodenoscopes
under the actual intended use conditions of SYSTEM 1E Liquid Chem-
ical Sterilant Processing System.
The data demonstrate that the SYSTEM 1E Liquid Chemical Ster-
ilant Processing System reliably achieves liquid chemical sterilization
of heavily contaminated duodenoscopes of varied designs under con-
ditions purposefully made more challenging than those normally
encountered in the clinical setting, while more accurately reﬂect-
ing certain conditions that may arise from clinical use. It is important
to note that this testing was conducted under conditions that do
not reﬂect the cleared instructions for use nor the standard cycle
of the SYSTEM 1E processor, but were designed to show the eﬃ-
cacy of the process under particular, rigorous test conditions.
Each validation test run was performed with large numbers of
Geobacillus stearothermophilus spores as the worst-case challenge
to peracetic acid-based liquid chemical disinfectants and steril-
ants (also steam sterilization), inoculated into areas of the devices
that are most challenging for the sterilant to penetrate, including
the length of every internal channel and the crevices around the
forceps elevator wire at the distal tip. Placement of an instrument
into the working channel, its repeated manipulation during inoc-
ulation, and a secondary channel inoculation via suctioning from
the distal tip up through the port of the duodenoscope ensured that
a heavy burden of spores would be recoverable from each of the
sites, and would represent a clinical soiling condition considered
especially challenging for the intricate distal tip design of the
duodenoscopes. Test organism spores were concentrated in the
aqueous inoculum to more than 1 × 108 CFU/mL, a titer targeted to
achieve a load of approximately 1 × 107 spores (in the presence of
organic and inorganic soil) on each distal tip site and in every in-
ternal channel of every duodenoscope using the validated inoculation
procedure. The total burden of most-diﬃcult-to-kill-spores on each
endoscope was therefore more than 10 times the load of ≥1 × 106
spores per device that is normally used for simulated use testing
in accord with recommendations of Guidance for Industry and FDA
reviewers in Content and Format of Premarket Notiﬁcation [510(k)]
Submissions for Liquid Chemical Sterilants/High Level Disinfectants
(January 3, 2000). Research previously published9 identiﬁed the mi-
crobial load on a cleaned device before reprocessing as typically 2
log10 CFU/cm2 (which represents 3.2-5.3 log10 CFU/endoscope
channel). Therefore, the microbial load used to challenge the
duodenoscopes in the tests reported here is much greater than what
would be experienced during normal use of the systemwith a prop-
erly cleaned device. Natural soil loads on clinically used devices
before manual cleaning differ in type and quantity from the test or-
ganisms used in this study; however, as noted previously, only
cleaned devices fall within the intended use of SYSTEM 1E.
The protocol included use of 5% serum in extremely hard water
(400 ppm), a medium typically used in this type of testing to rep-
resent potential organic and inorganic residues that could remain
in these hard-to-reach areas of the endoscope following cleaning.
After each inoculation, the endoscope was allowed to dry for at least
an hour. Despite this standard organic and inorganic load in the in-
oculum, it should be emphasized that this processing system is
Table 1










Distal end/elevator mechanism >6 >6
Biopsy/suction channel >7 >7
Air/water channel >7 >7
Pentax ED-3490TK
Distal end/elevator mechanism >6 >6
Biopsy/suction channel >8 >8
Air/water channel >7 >7
Olympus TJF-160F
Distal end/elevator mechanism >6 >6
Biopsy/suction channel >8 >8
Air/water channel >7 >7
Elevator guide wire channel >7 >7
*STERIS Corporation, Mentor, OH.
†Mean inoculumwas established by inoculation of the test device in the samemanner
as for the test runs, in triplicate. The device was not liquid chemically sterilized
between inoculation and harvest.
‡Mean log reduction is the difference between the mean recovered spore counts
(control) and the recovery after liquid chemical sterilization (test) runs.
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designed and labeled to liquid chemically sterilize only critical and
semicritical devices that are thoroughly cleaned; that is, SYSTEM
1E is not intended to clean soiled devices.
The cycles were run under worst-case conditions to achieve liquid
chemical sterilization, including exposure time, liquid circulation
pump rate, and water temperature. In addition, the S40 Sterilant
Concentrate used represented the lowest usable (end of shelf life)
peracetic acid concentration. The simulated use processing cycles
performed were interrupted after 2.5 minutes of sterilant expo-
sure, which is less than half the exposure time of the standard (6.0
minutes) SYSTEM 1E liquid chemical sterilization cycle. These pa-
rameters ensured that testing would validate SYSTEM 1E’s
performance with a wide margin of safety between the laboratory
setting and real-world use.
The use of these test conditions for the studies was proposed
by STERIS and accepted by the FDA. This testing is considered supple-
mental because it was performed to satisfy a speciﬁc FDA request,
yet does not replace the range of data submitted as the basis for
SYSTEM 1E’s original 2010 premarket clearance. That work in-
cluded simulated use testing of devices under static conditions; that
is, tested outside the S1E Processor, to minimize the natural effect
of wash-off associated with circulation of processing ﬂuids in the
automated system, a potential complication of device testing within
all liquid chemical processors. It should be noted that in the current
testing, some of the inoculated spore load (percentage not known)
may have been physically removed by the circulation of the per-
acetic acid-based solution around and through the duodenoscope
during the 2.5-minute exposure time. Despite this testing limita-
tion, in real-world use SYSTEM 1E’s tendency to wash away surface
residues with its oxidative sterilant use-dilution is generally con-
sidered a beneﬁcial feature.
CONCLUSIONS
The SYSTEM 1E Liquid Chemical Sterilant Processing Systemwas
validated to achieve more than 6 logs of spore reduction in each
internal channel and at the complex distal tip for varied
duodenoscope types, in less than half the exposure time normally
provided and in the presence of the worst-case parameters of
SYSTEM 1E processing. The successful outcome of the additional ef-
ﬁcacy testing reported here indicates that the SYSTEM 1E Liquid
Chemical Sterilant Processing System is an effective low-temperature
liquid chemical sterilization method for duodenoscopes and other
critical devices. It offers a fast, safe, convenient reprocessing method
with the assurance of a system expressly tested and cleared to
achieve liquid chemical sterilization of speciﬁc validated
duodenoscope models.
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